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OBJECTIVE: Refractory status epilepticus is one of the most life-threatening neurological emergencies and is
characterized by high morbidity and mortality. Additionally, the use of anti-inflammatory drugs during this
period is very controversial. Thus, this study has been designed to analyze the effect of a low dose of
indomethacin (a COX inhibitor) on the expression of inflammatory molecules.
METHOD: The hippocampus of rats submitted to pilocarpine-induced long-lasting status epilepticus was
analyzed to determine the expression of inflammatory molecules with RT-PCR and immunohistochemistry.
RESULTS: Compared with controls, reduced levels of the kinin B2 receptors IL1b and TNFa were found in the
hippocampus of rats submitted to long-lasting status epilepticus and treated with indomethacin.
CONCLUSIONS: These data show that low doses of indomethacin could be employed to minimize inflammation
during long-lasting status epilepticus.
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& INTRODUCTION
Epilepsy has traditionally been considered to be a
neuronal disease and several recent studies have suggested
that astrocytes, microglia, blood-derived leukocytes and
blood-brain barrier (BBB) breakdown are involved in the
pathogenesis of this disease (1,2). Experimental and clinical
evidence has demonstrated the increased synthesis of
specific inflammatory mediators and the upregulation of
their receptors in the epileptic brain, indicating that some
proinflammatory pathways are activated in seizure foci.
Patients with refractory temporal lobe epilepsy (TLE)
frequently present with hippocampal sclerosis (HS), which
has been related to high levels of IL1b and nitric oxide (NO)
in the hippocampal formation (3). Lymphocyte infiltrates
were also present in the hippocampus of these patients,
indicating that the immune system participates in this
disease.
Several molecules are involved in these proinflammatory
pathways, including molecules involved in disturbance to
the BBB, molecules in the cyclooxygenase (COX2) signaling
pathway, related prostaglandins, classical cytokines and
their downstream targets and toll-like receptors (1,4).
Refractory status epilepticus (SE) is one of the most life-
threatening neurological emergencies and it is characterized
by high morbidity and mortality (5). This severe condition
sometimes worsens the prognosis and, at times, long-lasting
seizures lead to refractory TLE in adulthood (6). Therefore,
several approaches have been used to diminish brain
sequelae due to SE. Treatment involves intravenous
anesthetics and antiepileptic drugs, including topiramate,
which has been associated with a decrease in tissue
excitability, blocking glutamate a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors (7).
Previous studies from our group have shown increased
levels of prostaglandin F2a (PGF2a) in the hippocampus of
rats submitted to pilocarpine-induced long-lasting SE (8). We
have also demonstrated that the administration of high doses
of indomethacin (a COX inhibitor) increases rat death due to
tonic seizures, blocking changes in the PG concentration.
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These data reveal the dual effect of anti-inflammatory drugs
in the treatment of epilepsy. In accordance with our previous
results, Jeong et al. (9) reported that acetylsalicylic acid
treatment also leads to increased death among epileptic
animals. In contrast, several authors have shown that COX2
inhibition can control P-glycoprotein (PgP) expression,
improving the penetration of antiepileptic drugs into the
brain and restoring the pharmacosensitivity to these drugs
(10,11). Additionally, COX2 deficiency reduces excitotoxic
damage to the epileptic brain (12). According to Levin et al.
(4), COX2 knockout mice presented with earlier mortality
after pilocarpine-induced SE. Dore´ et al. (13) also reported
that antagonists of the PGE2 receptor provide a neuropro-
tective effect, decreasing cell damage and reducing stroke
severity. These findings make this issue very controversial.
Thus, this study has been designed to analyze the effect of a
low dose of indomethacin on inflammatory molecule
expression in the hippocampus of rats submitted to
pilocarpine-induced, long-lasting SE.
& MATERIALS AND METHODS
Wistar rat treatment
The animal experiments were performed with institu-
tional ethics approval and all efforts were made to minimize
animal suffering. Moreover, the animals were given
assistance with eating and hydration during the initial
recovery period after SE to improve their condition and
endurance. Wistar adult male rats, weighing 250 g, were
housed in groups of three to four per cage and kept at a
controlled room temperature, humidity and light–dark cycle
(12512 h). Chow pellets and tap water were available ad
libitum. The rats received a single dose of pilocarpine
(350 mg/kg, intraperitoneal [i.p.]). To prevent peripheral
cholinergic effects, scopolamine methyl nitrate was sub-
cutaneously injected at a dose of 1 mg/kg 30 min before
pilocarpine administration. Animals that progressed to SE
were divided into two groups: pilo (group B) and
pilo+indomethacin (group C) (0.5 mg/kg i.p.). The indo-
methacin was injected at different time intervals after SE
(30 min, 1 h, 2 h and 4 h). The animals were sacrificed 5 h
after SE. Saline-treated animals (group A) were sacrificed
5 h after saline and scopolamine methyl nitrate injections
and were used as control groups.
These groups were used to quantify the mRNA levels of
kinin B1 and B2 receptors, TNFa and IL-1b with a real-time
PCR assay (n = 4 per group). The spatial and temporal
localization of both kinin receptors and cytokines were
analyzed using immunohistochemistry (n = 3 per group).
Quantitative real-time TaqmanTM PCR
For the biochemical evaluation of kinin B1 and B2
receptors, TNFa and IL-1b, brains were collected from the
following groups: saline-treated rats (control group; group
A); animals that received scopolamine methyl nitrate plus
pilocarpine injection (350 mg/kg i.p.) and were sacrificed
5 h after SE onset (pilocarpine-treated group; group B); and
animals that received scopolamine methyl nitrate plus
pilocarpine injection (350 mg/kg i.p.) plus indomethacin
(0.5 mg/kg i.p.) (indomethacin-treated group; group C).
Rats from the aforementioned groups (n = 4 for each group)
were sacrificed and their brains were isolated and dissected.
Rat hippocampi were then frozen in liquid nitrogen and
stored at -80 C˚. Thawed tissue was homogenized in 1 ml of
TRIzol reagent (Gibco BRL, Gaithersburg, MD) and total
RNA was isolated according to the manufacturer’s instruc-
tions. Samples were amplified in 20 ml reactions using the
TaqMan
TM
Amplification System with an ABI PRISMH 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Real-time PCR was performed with 900 ng
of cDNA for kinin B1 and B2 receptors, IL1b and TNFa,
whereas 100 ng of cDNA was used for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), which served as an
internal standard. Oligonucleotide primer and fluorogenic
probe sets for TaqmanTM Real-Time PCR were designed for
kinin receptors and GAPDH using the Assays-by-Design
Service (Applied Biosystems) to meet all TaqmanTM design
guidelines. Probes were synthesized with the reporter dye
6-carboxyfluorescein (6-FAM) covalently linked to the 59
end and the quencher dye 6-carboxy-tetramethyl-rhoda-
mine (TAMRA) linked to the 39 end of the probe. Each
reaction was carried out with 10 ml of Master Mix (Applied
Biosystems), 1 ml of a mix containing two primers (18 ml
each) and a probe 5 ml specific to mRNA of Kinin B1
receptor (forward primer: 59-CCAGGGTTCGTCATCACT-
ATCTG-39, reverse primer: 59-GCAAAAGGAAGAAGGAC-
AAGACTAA-39), the kinin B2 receptor (forward primer: 59-
CCCTTCCTCTGGGTCCTCTT-39, reverse primer: 59-CAG-
AACACGCTGAGGACAAAGA-3), IL-1b (forward primer:
59-CACCTCTCAAGCAGAGCACAG-39, reverse primer: 59-
GGGTTCCATG GTGAAGTCAAC-39), TNFa (forward
primer: 59- AAATGGGCTCCCTCTATCAGTTC-39, reverse
primer: 59-TCTGCTTGGTGGTTTGCTACGAC- 39), or
GAPDH (forward primer: 59-GGGCAGCCCAGAACATC-
AT-39, reverse primer: 59-CCGTTCAGCTCTGGGATGAC-
39). The cycling conditions were as follows: 50 C˚ for 2 min
and 95 C˚ for 10 min, followed by 50 cycles of 95 C˚ for 15 s
(melting step) and 60 C˚ for 1 min (annealing/extension step).
Data analysis
Increases in the level of reporter dye fluorescence during
the 50 cycles of amplification were monitored using
Sequence Detector Software (SDS version 1.6; Applied
Biosystems). The PCR amplification cycle in which a given
fluorescence threshold is reached is the first parameter used
for analyzing mRNA expression and is referred to as Ct. The
higher the initial copy level, the lower the Ct value. A
normalized value is obtained by subtracting the Ct of
GAPDH from the Ct of kinin B1, B2, IL-1b or TNFa,
resulting in the DCt. It is uncommon to use DCt as a
measure of relative expression due to its logarithmic nature;
thus, the 2-DCt parameter is used to express the relative
expression level (14). The mRNA expression levels of the
kinin B1 and B2 receptors and cytokines are presented as n-
fold differences relative to the levels expressed during
different experimental model phases and were compared
using one-way ANOVA followed by Tukey’s post-test. The
data are presented as the means ¡ S.E.M.; p,0.05 was
considered statistically significant.
Immunohistochemistry
Immunohistochemistry, as a non-quantitative method,
was employed to analyze alterations in the spatial and
temporal distribution of the kinin B1 and B2 receptors,
TNFa and IL-1b in all studied groups. The rats were
anesthetized and transcardially perfused with PBS (phos-
phate-buffered saline, 15 ml) followed by 4% paraformal-
dehyde (40 ml). The brains were removed immediately after
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perfusion and post-fixed in paraformaldehyde (4%). The
brains were sectioned at 40 mm, collected and washed with
PBS (pH 7.4). All sections were treated with 3% H2O2 in PBS
to quench the endogenous peroxidase and were then
incubated for 2 h in PBS containing 0.3% Triton X-100 and
bovine serum albumin. Subsequently, the sections were
incubated overnight at 4 C˚ with the following primary
antibodies: anti-B2 receptor (BD Transduction) diluted
15100, anti-IL1b (IBL) diluted 15100, anti-TNFa (IBL)
diluted 15100 and anti-B1 (Santa Cruz) diluted 1550 in 2%
albumin. After three washes in PBS, the sections were
incubated with the secondary biotinylated antibody for 2 h.
The complex was then incubated with the ABC Kit (Vector)
and visualized using 3,39-diaminobenzidine (1 mg/ml in
1% H2O2). The sections were subsequently dehydrated,
coverslipped and analyzed by light microscopy using
bright-field illumination.
& RESULTS
Immunoreactivity of the kinin B1 and B2 receptors,
IL-1b and TNFa in the hippocampus
Immunohistochemical analysis revealed the distribution
of the kinin B1 receptor in all hippocampal formations of all
studied groups (Figure 1, panel A–C). Regions such as CA1,
CA2, CA3 and the hilus as well as the granular cells from
the dentate gyrus were stained. However, the staining
intensity of kinin B1 was very different among the groups
studied. Increased immunoreactivity was observed in
the CA1 region of rats in groups B and C (Figure 2,
panels A-C). On the other hand, the CA3 region showed
less immunoreactivity for the kinin B1 receptor when
groups B and C were compared with group A (Figure 3,
panels A-C).
Immunoreactivity for the kinin B2 receptor was also
visualized in all hippocampal formations of all studied
groups (Figure 1, panels A’-C’). Increased staining was
noted in the CA1 and CA3 regions of rats from group B
compared with rats from group A (Figures 2 and 3, panels
A’-B’).
Immunohistochemical analysis of IL-1b showed increased
staining in the CA1 region of rats from group B compared
with those of group A (Figures 2 and 3, A’’-C’’).
TNFa staining was decreased in the CA3 of rats from
groups B and C compared with rats from group A (Figure 3,
panels A’’’-C’’’). Interestingly, the CA1 and CA2 regions
were not labeled by TNFa antibody. Note that all
hippocampal regions of rats treated with indomethacin
had decreased levels of cytokines.
Real-time PCR analysis of the kinin B1 and B2
receptors, IL-1b and TNFa
The mRNA levels of the kinin receptors, IL1b and TNFa
in Wistar rats were analyzed using a semi-quantitative RNA
assay. There were no alterations in kinin B1 mRNA in any of
the groups that were studied (Figure 4 A). The kinin B2
receptor mRNA level was increased in group B
(1.565¡0.2841) compared with group A (1.042¡ 0.2057)
(p,0.05) (Figure 4 B). However, when comparing the
animals in group B (1.565¡0.2841) with those in group C
(1.038¡0.1857), we observed a decrease in the expression of
this receptor (p,0.05) (Figure 4 B). There was an increase in
Figure 1 - Photomicrographs of hippocampi processed for immunohistochemistry showing expression of the kinin B1 receptor (A, B and
C), the kinin B2 receptor (A’, B’ and C’), IL1b (A’’, B’’ and C’’) and TNFa (A’’’, B’’’ and C’’’). Groups: A – saline-treated group; B –
pilocarpine-treated group; and C – indomethacin-treated group. Scale bars: 0.3 mm.
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the IL-1b mRNA in group B (0.4450¡0.1622) compared with
group A (0.2150¡0.09950) (p,0.05) (Figure 5 A). On the
other hand, the level of IL-1b mRNA was decreased in
group C (0.1850¡0.06608) compared with group B
(0.4450¡0.1622) (p,0.05) (Figure 5 A). Quantitative real-
time PCR also revealed a significant increase in the mRNA
expression of TNFa in the animals in group B
(0.6275¡0.2364) compared with those in group A
(0.2700¡0.09661) (p,0.05) (Figure 5 B). When the animals
in group B (0.6275¡0.2364) were compared with the
animals in group C (0.3325¡0.1284), no differences in
TNFa expression levels were observed.
Figure 2 - Photomicrographs of the CA1 region of hippocampi processed for immunohistochemistry showing expression of the kinin B1
receptor (A, B and C), the kinin B2 receptor (A’, B’ and C’) and IL1b (A’’, B’’ and C’’). Groups: A – saline-treated group; B – pilocarpine-
treated group; and C – indomethacin-treated group. Scale bars: 0.02 mm.
Figure 3 - Photomicrographs of the CA3 region of hippocampi processed for immunohistochemistry showing expression of the kinin B1
receptor (A, B and C), the kinin B2 receptor (A’, B’ and C’), IL1b (A’’, B’’ and C’’) and TNFa (A’’’, B’’’ and C’’’). Groups: A – saline-treated
group; B – pilocarpine-treated group; and C – indomethacin-treated group. Scale bars: 0.02 mm.
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& DISCUSSION
In this study, we found that rats submitted to long-lasting
SE exhibited increased expression of IL1b and TNFa, as
previously reported by other authors. These cytokines are
related to pro-convulsing action (15), increased excitotoxi-
city, inhibition of glutamate uptake by astrocytes and
decreased GABA release (16,17). We also found that the
administration of indomethacin (a non-selective COX
inhibitor) reduced IL1b and TNFa synthesis and expression,
providing neuroprotection against inflammatory processes.
With respect to the kinin B1 and B2 receptors, only the B2
receptor was upregulated by SE and indomethacin admin-
istration returned this receptor to its normal levels. These
data show that the inflammation-induced kinin B1 receptor
is not modulated by this drug. Because the kinin B2 receptor
has been considered to play a protective role in the nervous
system (18), its downregulation by indomethacin seems to
be a maladaptive process.
In a lithium plus pilocarpine model of epilepsy,
Voutsinos-Porche et al. (19) found increased expression of
IL1b, NFkb and COX2 in structures that are prone to
develop neuronal damage and in activated astrocytes. COX2
inhibitors such as parecoxib have neuroprotective effects,
but they have not been effective in modifying epileptogen-
esis in a pilocarpine-model of epilepsy (20). Other authors
who used the selective COX2 inhibitor SC58236 have shown
that this inhibition does not modify either the epileptogenic
process or the frequency of chronic seizures (21). In contrast,
Okada et al. (22) used indomethacin and observed a
reduction in the seizure duration in mice that were
genetically susceptible to seizures.
Zibell et al. (23) demonstrated that seizure activity
induces the expression of the BBB efflux transporter P-
glycoprotein (Pgp), limiting the penetration of antiepileptic
drugs into the brain. This induction was associated with the
activation of NMDA glutamate receptors as well as COX2
and arachidonic acid production. In this way, the highly
Figure 4 - mRNA expression levels of the kinin B1 receptor (A) and kinin B2 receptor (B) in the hippocampus of rats in the pilocarpine
model of epilepsy as evaluated with a real-time PCR assay. All data have been normalized to the levels of GAPDH. The data are
presented as the mean¡S.E.M. (n = 5 per group).
Figure 5 - mRNA expression levels of IL1b (A) and TNFa (B) in the hippocampus of rats in the pilocarpine model of epilepsy as evaluated
with a real-time PCR assay. All data have been normalized for the levels of GAPDH expression. Data are given as the mean¡S.E.M. (n = 5
per group). * p,0.05.
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selective COX2 inhibitor NS-398, an indomethacin-related
molecule, blocked the overexpression of Pgp in pilocarpine-
induced seizures.
Taken together, these data show that the inhibition of
COX during the development of neurodegenerative pro-
cesses can be dose- and time-dependent, which was
reported previously by other authors (23,24). As reported
by our group (8), the administration of high doses of
indomethacin prior to pilocarpine injection increases the
mortality rate due to tonic seizures in rats, indicating a dual
effect involving COX inhibition in this epileptic model.
Additionally, numerous specific cell types, including
neurons of various subcategories and different glial cells,
express and respond to inflammatory mediators in dis-
tinctly different ways. Therefore, a given molecule might be
beneficial for a particular population of cells but harmful for
other populations (25). Several authors have debated the
efficacy of anti-inflammatory drugs in epilepsy treatment,
highlighting the antiepileptic action of some types of PGs,
such as PGD2 and PGE2, but noting that PGs may
contribute to the feedback inhibition of neurotransmitter
release, possibly reducing excitation (26). In this sense, the
blockage of or decrease in COX activity in the early stages of
SE, which reduces the levels of inflammatory mediators,
seems to be insufficient for blocking epileptogenesis, but it
could be effective in neuronal protection or for the control of
otherwise refractory seizures.
Therefore, our data show that the administration of
indomethacin decreases the levels of inflammatory media-
tors when used in the early phases of SE onset in an epilepsy
model induced by pilocarpine. However, caution should be
exercised when using anti-inflammatory drugs in epilepsy
because several pathways are activated during this process.
& ACKNOWLEDGMENTS
This work was supported by Fundac¸a˜o de Amparo a Pesquisa do Estado de
Sa˜o Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientı´fico e
Tecnolo´gico (CNPQ), Institutos Nacionais de Cieˆncia e Tecnologia
(INCT) and Programa de Apoio a Nu´cleos de Exceleˆncia (PRONEX).
& AUTHOR CONTRIBUTIONS
Vieira MJ and Perosa SR developed the experimental model of epilepsy
and the immunohistochemistry protocol; additionally, they assisted with
manuscript writing. Silva Jr JA performed real-time PCR. Cavalheiro EA,
Argan˜araz GA and Naffah-Mazzacoratti MG outlined the main ideas and
wrote the manuscript.
& REFERENCES
1. Friedman A, Dingledine R. Molecular cascades that mediate the
influence of inflammation on epilepsy. Epilepsia. 2011;52 Suppl 3:33-9,
http://dx.doi.org/10.1111/j.1528-1167.2011.03034.x.
2. Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic
autoimmune disorders. Epilepsy Curr. 2013;13(2):62-8, http://dx.doi.
org/10.5698/1535-7597-13.2.62.
3. Varella PP, Santiago JF, Carrete H Jr., Yacubian EM, Centeno RS, Caboclo
LO, et al. Relationship between fluid-attenuated inversion-recovery
(FLAIR) signal intensity and inflammatory mediator’s levels in the
hippocampus of patients with temporal lobe epilepsy and mesial
temporal sclerosis. Arq Neuropsiquiatr. 2011;69(1):91-9, http://dx.doi.
org/10.1590/S0004-282X2011000100018.
4. Levin JR, Serrano G, Dingledine R. Reduction in delayed mortality and
subtle improvement in retrograde memory performance in pilocarpine-
treated mice with conditional neuronal deletion of cyclooxygenase-2
gene. Epilepsia. 2012;53(8):1411-20, http://dx.doi.org/10.1111/j.1528-
1167.2012.03584.x.
5. Sutter R1, Marsch S, Fuhr P, Ru¨egg S. Mortality and recovery from
refractory status epilepticus in the intensive care unit: a 7-year
observational study. Epilepsia. 2013;54(3):502-11.
6. Cendes F, Ragazzo PC, da Costa V, Martins LF. Corpus callosotomy in
treatment of medically resistant epilepsy: preliminary results in a
pediatric population. Epilepsia. 1993;34(5):910-7, http://dx.doi.org/10.
1111/j.1528-1157.1993.tb02111.x.
7. Hottinger A, Sutter R, Marsch S, Ru¨egg S. Topiramate as an adjunctive
treatment in patients with refractory status epilepticus: an observational
cohort study. CNS Drugs. 2012;26(9):761-72, http://dx.doi.org/10.2165/
11633090-000000000-00000.
8. Naffah-Mazzacoratti MG, Bellı´ssimo MI, Cavalheiro EA. Profile of
prostaglandin levels in the rat hippocampus in pilocarpine model of
epilepsy. Neurochem Int. 1995;27(6):461-6, http://dx.doi.org/10.1016/
0197-0186(95)80003-4.
9. Jeong KH, Kim JY, Choi YS, Lee MY, Kim SY. Influence of aspirin on
pilocarpine-induced epilepsy in mice. Korean J Physiol Pharmacol.
2013;17(1):15-21.
10. Zibell G, Unkru¨er B, Pekcec A, Hartz AM, Bauer B, Miller DS, et al.
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein
by COX-2 inhibition. Neuropharmacology. 2009;56(5):849-55, http://dx.
doi.org/10.1016/j.neuropharm.2009.01.009.
11. Schlichtiger J, Pekcec A, Bartmann H, Winter P, Fuest C, Soerensen J,
Potschka H. et al. Celecoxib treatment restores pharmacosensitivity
in a rat model of pharmacoresistant epilepsy. Br J Pharmacol.
2011;60(5):1062-71.
12. Takemiya T, Maehara M, Matsumura K, Yasuda S, Sugiura H, Yamagata
K. Prostaglandin E2 produced by late induced COX-2 stimulates
hippocampal neuron loss after seizure in the CA3 region. Neurosci
Res. 2006;56(1):103-10, http://dx.doi.org/10.1016/j.neures.2006.06.003.
13. Dore´ S. GPCR antagonists as an alternative to COX-2 inhibitors: a case
for the PGE2 EP1 receptor. Trends Pharmacol Sci. 2006;27(9):458-60,
http://dx.doi.org/10.1016/j.tips.2006.07.001.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods. 2001;25(4):402-8, http://dx.doi.org/10.1006/meth.2001.1262.
15. Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, et al.
Interleukin-1beta immunoreactivity and microglia are enhanced in the
rat hippocampus by focal kainate application: functional evidence for
enhancement of electrographic seizures. J Neurosci. 1999;19(12):5054-65.
16. Ye ZC, Sontheimer H. Cytokine modulation of glial glutamate uptake: a
possible involvement of nitric oxide. Neuroreport. 1996;7(13):2181-5,
http://dx.doi.org/10.1097/00001756-199609020-00025.
17. Zeise ML, Espinoza J, Morales P, Nalli A. Interleukin-1beta does not
increase synaptic inhibition in hippocampal CA3 pyramidal and dentate
gyrus granule cells of the rat in vitro. Brain Res. 1997;768(1-2):341-4.
18. Argan˜araz GA, Regina Perosa S, Cristina Lencioni E, Bader M, Abra˜o
Cavalheiro E, da Grac¸a Naffah-Mazzacoratti M, et al. Role of kinin B1
and B2 receptors in the development of pilocarpine model of epilepsy.
Brain Res. 2004;1013(1):30-9.
19. Voutsinos-Porche B, Koning E, Kaplan H, Ferrandon A, Guenounou M,
Nehlig A, et al. Temporal patterns of the cerebral inflammatory response
in the rat lithium-pilocarpine model of temporal lobe epilepsy.
Neurobiol Dis. 2004;17(3):385-402, http://dx.doi.org/10.1016/j.nbd.
2004.07.023.
20. Polascheck N, Bankstahl M, Lo¨scher W. The COX-2 inhibitor parecoxib is
neuroprotective but not antiepileptogenic in the pilocarpine model of
temporal lobe epilepsy. Exp Neurol. 2010;224(1):219-33, http://dx.doi.
org/10.1016/j.expneurol.2010.03.014.
21. Holtman L, van Vliet EA, van Schaik R, Queiroz CM, Aronica E, Gorter
JA. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis
and spontaneous seizures in a rat model for temporal lobe epilepsy.
Epilepsy Res. 2009;84(1):56-66, http://dx.doi.org/10.1016/j.eplepsyres.
2008.12.006.
22. Okada K, Yamashita U, Tsuji S. Cyclooxygenase system contributes to
the maintenance of post convulsive period of epileptic phenomena in the
genetically epileptic El mice. J UOEH. 2006;28(3):265-75.
23. Baran H, Vass K, Lassmann H, Hornykiewicz O. The cyclooxygenase
and lipoxygenase inhibitor BW755C protects rats against kainic acid-
induced seizures and neurotoxicity. Brain Res. 1994;646(2):201-6.
24. Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, Makinson CD, et al.
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective
and dampens brain inflammation after status epilepticus. J Neurosci.
2011;31(42):14850-60, http://dx.doi.org/10.1523/JNEUROSCI.3922-11.
2011.
25. Dedeurwaerdere S, Callaghan PD, Pham T, Rahardjo GL, Amhaoul H,
Berghofer P, et al. PET imaging of brain inflammation during early
epileptogenesis in a rat model of temporal lobe epilepsy. EJNMMI Res.
2012;2(1):60, http://dx.doi.org/10.1186/2191-219X-2-60.
26. Herting G, Seregi A. Formation of eicosanoids in central nervous system.
In: Arachidonic acid Metabolism in Nervous System (Barkai A.I and
Bazan N. eds) New York Academy of Science, New York. 1989;84-99.
Indomethacin, inflammation, temporal lobe epilepsy
Vieira MJ et al.
CLINICS 2014;69(9):621-626
626
